RPL22 and cancer: Inflammation is an established driver of many cancers including those of the liver [114–118] and NF-κB has been shown to promote HCC in the setting of cholestatic-induced liver injury akin to that seen in ΔS6 livers [119] as well as in the setting of Rpl22-deficiency via induction of the pluripotency factor Lin28b [120].